Hot Stock to Watch: MannKind Corp. (MNKD)

Mae Love
November 14, 2017

Short shares increased from 23,671,860 to 26,337,802 over that period.

The Price to book ratio is the current share price of a company divided by the book value per share. EPS is generally considered to be the only most important variable in determining a share's price.

A number of equities analysts recently weighed in on the company. Finally, Maxim Group reaffirmed a "hold" rating on shares of MannKind Corporation in a report on Wednesday. HC Wainwright assumed coverage on MannKind Corporation in a report on Tuesday, October 10th. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

Whereas its latest closing price kept its distance from the SMA20 at -3.98% and -8.13% from SMA 50 while it was knocked up -29.47% from the simple moving average price of 200 days.

In other news, Director Kent Kresa acquired 166,600 shares of the business's stock in a transaction on Friday, October 13th. The mean rating score for this stock is at 1.90.

A number of institutional investors and hedge funds have recently modified their holdings of MNKD. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company's stock worth $196,000 after acquiring an additional 30,589 shares in the last quarter.

Shares of MannKind Corporation (NASDAQ:MNKD) have been given a consensus recommendation of "Hold" by the seven analysts that are covering the firm, reports. Looking further out we can see that the stock has moved over the year to date. Finally, Bank of New York Mellon Corp lifted its holdings in shares of MannKind Corporation by 30.2% in the third quarter.

Embarrassment for Congress as party member represents tainted Kerala Minister
According to reports in the media, it is in this context that the minister is mulling over moving the supreme court . Peethamabaran said a decision on Chandy would be taken by the NCP parliamentary board.

China calls for advancing free trade talks with South Korea, Japan
South Korean President Moon Jae-in and Chinese President Xi Jinping had a summit meeting in Da Nang, Vietnam on November 11. The tensions triggered by North Korea's missile tests were not mentioned during the opening statements of Duterte and Moon.

'Padamavati' row intensifies; Rajput group vandalises theatre screening trailer
Following the protest, the screening of the teaser has been stopped at the theatre, the police officer said. They had issued warnings that they would set theatres on fire if the movie was screened.

For the Current Quarter, the growth estimate for MannKind -137.5%, while for the Next Quarter the stock growth estimate is -52.9%.

Several other institutional investors have also sold shares of the company.

DEERFIELD MANAGEMENT CO raised its stake in MannKind Corporation (NASDAQ:MNKD) by New% during the June 2017 quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Its book value per share for the most recent quarter is $-2.4 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.17, however its price to cash per share ratio for the same period is 18.63. The company has a quick ratio of 0.28, a current ratio of 0.31 and a debt-to-equity ratio of -0.43. MannKind Corporation has a one year low of $0.67 and a one year high of $6.96. During previous trade 6.26 Million shares of Mannkind Corporation (NASDAQ:MNKD) exchanged hands whereas on average nearly 8.25 Million shares has been traded. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.10). MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%. The mean target price as estimated by the analysts for the company has been recorded at $48.18.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year's free cash flow.

According to data from Finviz's Research, The price target set for the stock is $7.00 and this sets up an interesting set of potential movement for the stock.

TRADEMARK VIOLATION WARNING: "Short Interest in MannKind Corporation (MNKD) Increases By 11.3%" was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally stolen and republished in violation of USA & worldwide copyright legislation. The MannKind Corporation has Relative Strength Index (RSI 14) of 45.42 along with Average True Range (ATR 14) of 0.56. The Firm is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Business's product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control.

Other reports by

Discuss This Article